Where does Hybio Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Hybio Pharmaceutical Co., Ltd. ranks #24,494 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Hybio Pharmaceutical Co., Ltd. hold?

Hybio Pharmaceutical Co., Ltd. holds 11 US utility patents granted between 2016 and 2022, spanning 12 technology areas.

What is Hybio Pharmaceutical Co., Ltd.'s Innovation Score?

Hybio Pharmaceutical Co., Ltd. has an Innovation Score of 28.6 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Hybio Pharmaceutical Co., Ltd. focus on?

Hybio Pharmaceutical Co., Ltd.'s top technology area is C07K (Peptides) with 10 patents, ranking #887 of 3,615 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Hybio Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Hybio Pharmaceutical Co., Ltd.'s recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Hybio Pharmaceutical Co., Ltd.'s patents?

Hybio Pharmaceutical Co., Ltd.'s patents average 11.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Hybio Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hybio Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 11 granted patents across 12 technology areas, recorded in grant years 2016–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hybio ranks #24,494 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 12 technology areas.

#24,494
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.6/100): 11.2
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24494 · Foreign Corporation #24,494 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,494/49,997
PHOTO-FINISH Horus Pharma
CPC-FOCUS C07K · 12 areas
INNOV-THIN 28.6/100
CLAIMS-PAR 11.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Horus Pharma (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hybio’s 28.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (30%) Velocity 1.1 pts (4%) Breadth 12.2 pts (43%) Claim depth 6.7 pts (23%)

Qualcomm Incorporated · highest

85
Hybio Pharmaceutical · this assignee

29
3D Lighting… · lowest

7

What this shows Hybio's Innovation Score is 28.6/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Hybio?

Each dot is one of Hybio’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hybio’s own 11.2 claims/patent is at or below the 14.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Hybio vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hybio's grants concentrate

Hybio Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 12 CPC subclasses with 90.9% of grants classified under C07K (Peptides). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2022. By volume, Hybio sits between Horus Pharma and I-interactive LLC.

Hybio's three-year grant acceleration

Hybio Pharmaceutical Co., Ltd. shows 1 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Horus Pharma

11
Huf Baolong Brett…

11
Huffy

11
Hurley Internatio…

11
Hydro Aluminium D…

11
Hyster-yale Mater…

11
I-blades

11
I-interactive

11
Hybio Pharmaceuti… ◀

11

What this shows Hybio holds 11 patents at rank #24,494, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Hybio

By rank, the assignees closest to #24,494 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Hybio's primary technology class.

Hybio's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Hybio Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	18.2%
2017	2	18.2%
2019	4	36.4%
2020	2	18.2%
2022	1	9.1%

Which technologies does Hybio Pharmaceutical Co., Ltd. patent most?

C07K - Peptides 10

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

B01D - Separation 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07C - Acyclic OR Carbocyclic Compounds 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

C12Y - Enzymes 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hybio Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Hybio Pharmaceutical Co., Ltd.'s lead technology class is C07K (Peptides), 90.9% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #24,494 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Hybio Pharmaceutical Co., Ltd. against Horus Pharma, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.